Skip to main content

Table 1 Baseline characteristics for all patients

From: Short-term and long-term outcomes of liver resection for HCC patients with portal vein tumor thrombus

Variable

Overall

(N = 457)

Alive

(n = 139)

Died

(n = 318)

P

Age, years

47.9 ± 10.3

47.6 ± 9.38

48.1 ± 10.7

0.612

Sex

0.378

 Female

50 (10.9%)

12 (8.6%)

38 (11.9%)

 

 Male

407 (89.1%)

127 (91.4%)

280 (88.1%)

 

Viral marker

    

 HBsAg positive

420 (92.7%)

131 (94.2%)

289 (92.0%)

0.524

 Anti-HCV positive

3 (0.7%)

1 (0.7%)

2 (0.6%)

1.000

AFP, μg/L

1210 (1.2–777,600)

1067 (1.2–37,073)

1210 (1.8–777,600)

0.034

AFP, Log 10 μg/L

3.08 (0.08–5.89)

3.03 (0.08–4.57)

3.08 (0.26–5.89)

0.034

TBIL, mg/dL

0.81 (0.26–7.54)

0.77 (0.26–1.87)

0.83 (0.30–7.54)

0.023

ALB, g/L

41.0 (17.2–67.2)

41.3 (17.2–67.2)

40.8 (17.8–65.3)

0.169

PT, s

12.2 (9.6–18.0)

12.2 (10.2–15.2)

12.3 (9.6–18.0)

0.411

ALT, U/L

42.6 (8.7–187.8)

42.1 (11.2–187.8)

42.7 (8.7–169.9)

0.965

PLT, 109/L

156 (25.0–629)

156 (25.0–369)

156 (25.0–629)

0.957

WBC, 109/L

5.51 (1.44–19.4)

5.40 (1.63–11.8)

5.54 (1.44–19.4)

0.187

Hemoglobin, g/L

141 (75.0–195.0)

142 (104.0–174.0)

141 (75.0–195.0)

0.988

Child–Pugh class

0.288

 A

448 (98.0%)

138 (99.3%)

310 (97.5%)

 

 B

9 (2.0%)

1 (0.7%)

8 (2.5%)

 

Radiologic ascites

0.019

 No

422 (92.3%)

135 (97.1%)

287 (90.3%)

 

 Mild

35 (7.66%)

4 (2.88%)

31 (9.75%)

 

Gastroesophageal varices

1.000

 No

382 (83.6%)

116 (83.5%)

266 (83.6%)

 

 Yes

75 (16.4%)

23 (16.5%)

52 (16.4%)

 

Radiologic spleen length, cm

11.4 (6.30–20.2)

11.0 (6.30–17.5)

11.6 (6.30–20.2)

0.060

CSPH

0.237

 No

233 (51.0%)

79 (56.8%)

154 (48.4%)

 

 Mild

183 (40.0%)

48 (34.5%)

135 (42.5%)

 

 Severe

41 (9.0%)

12 (8.6%)

29 (9.1%)

 

Type of hepatectomy

0.177

 En bloc resection

289 (63.2%)

81 (58.3%)

208 (65.4%)

 

 Non-en bloc resection

168 (36.8%)

58 (41.7%)

110 (34.6%)

 

Operating time, h

2.0 (0.45–20.8)

2.0 (0.45–20.8)

2.0 (0.45–20.8)

0.175

Hilar clamping time, min

20.0 (0–83.0)

21.0 (0–48.0)

20.0 (0–83.0)

0.248

Intraoperative blood loss, mL

400 (0–45,000)

400 (10–3200)

400 (0–45,000)

0.181

Transfusion

0.229

 No

326 (71.3%)

105 (75.5%)

221 (69.5%)

 

 Yes

131 (28.7%)

34 (24.5%)

97 (30.5%)

 

Surgical margins

0.115

 R0

363 (79.4%)

115 (82.7%)

248 (78.0%)

 

 R1

16 (3.5%)

7 (5.1%)

9 (2.8%)

 

 Unconfirmed

78 (17.1%)

17 (12.2%)

61 (19.2%)

 

Extent of PVTT

0.523

 Left branch

102 (22.3%)

27 (19.4%)

75 (23.6%)

 

 Right branch

256 (56.0%)

83 (59.7%)

173 (54.4%)

 

 Main trunck/contralateral branch

99 (21.7%)

29 (20.9%)

70 (22.0%)

 

Tumor number

0.283

 Solitary

413 (90.4%)

122 (87.8%)

291 (91.5%)

 

 Multiple

44 (9.6%)

17 (12.2%)

27 (8.49%)

 

Tumor diameter, cm

8.3 (0.4–24.0)

7.5 (0.6–22.0)

9.0 (0.4–24.0)

0.004

Cirrhosis

0.295

 No

131 (28.7%)

45 (32.4%)

86 (27.0%)

 

 Yes

326 (71.3%)

94 (67.6%)

232 (73.0%)

 

Tumor differentiation

0.647

 II

24 (5.3%)

9 (6.5%)

15 (4.7%)

 

 III

425 (93.0%)

127 (91.4%)

298 (93.7%)

 

 IV

8 (1.7%)

3 (2.1%)

5 (1.6%)

 
  1. HBsAg hepatitis B surface antigen, anti-HCV hepatitis C virus antibody, AFP α-fetoprotein, TBIL total bilirubin, ALB albumin, PT pro-thrombin time, ALT alanine aminotransferase, PLT platelet count, WBC white blood cell, CSPH clinical significant portal hypertension, PVTT portal vein tumor thrombus